• HUTCHMED entered an exclusive licensing deal with GSK for HMPL-A830, a KRAS-EGFR antibody-drug conjugate cancer therapy.
• GSK received worldwide rights excluding Mainland China, Hong Kong, Macau, Taiwan; HUTCHMED kept rights in those markets.
• Deal includes USD 110 million upfront; milestones up to USD 1.19 billion; total potential consideration up to USD 1.3 billion.
• HUTCHMED will run global Phase I starting H2 2026; GSK takes later-stage development, regulatory work, commercialization outside retained territories.
• Clinical focus initially targets colorectal cancer, pancreatic cancer, lung cancer; GSK also secured a right of first negotiation on another ATTC candidate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609030000PRIMZONEFULLFEED9820817) on September 03, 2026, and is solely responsible for the information contained therein.